Q3FY17 results : Lupin
Bhagyashree Vivarekar / 09 Feb 2017
The company reported a PAT figure of Rs 633 crore which represents a sequential QoQ decline of 3.95 percent and a YoY increase of 20.57 per cent.
Lupin Pharmaceuticals, Inc. showed stellar performance in Q3FY17. Lupin reported its consolidated results for the quarter ended December 31, 2016 on Thursday. The company's sales for this quarter, Q3FY17, came in at Rs 4,483 crore. This represents a 4.47
Its operating profit (EBIT) for the recently concluded quarter amounted to Rs 985 crore and the EBIT margin stood at 21.97 per cent. In terms of the bottom-line, the company reported a PAT figure of Rs 633 crore which represents a sequential QoQ decline of 3.95 per cent and a YoY increase of 20.57 per cent.
Lupin is now the market leader in 45 products in the US generics market and amongst top 3 in 78 of its products. (market share by prescription, IMS Health, December 2016).
Lupin Limited is an Indian Pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs. The company focuses on tuberculosis drugs, cardiovascular (
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.